Regulation of phosphoinositide 3-kinase expression in health and disease

Trends in Biochemical Sciences

Volumn 34, Issue 3, 2009, Pages 115-127

  Kok, Klaartje ^a,b   Geering, Barbara ^c   Vanhaesebroeck, Bart ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; ALITRETINOIN; BEXAROTENE; CELL NUCLEUS RECEPTOR; DEOXYCORTICOSTERONE ACETATE; EPSTEIN BARR VIRUS ANTIGEN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIRINIXIC ACID; PROTEIN P110; PROTEIN P110ALPHA; PROTEIN P110BETA; PROTEIN P110DELTA; PROTEIN P110GAMMA; PROTEIN P50ALPHA; PROTEIN P53; PROTEIN P55ALPHA; PROTEIN P85BETA; RETINOIC ACID; RIMONABANT; ROSIGLITAZONE; STAT3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL REGENERATION; CELL STIMULATION; CELL TYPE; DIABETES MELLITUS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME REGULATION; ENZYME SYNTHESIS; GENE AMPLIFICATION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HYPERTENSION; LEUKEMIA CELL; LUNG CANCER; NEOPLASM; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; STOMACH CARCINOMA; THYROID CANCER; TISSUE DISTRIBUTION; TRANSCRIPTION REGULATION; UTERINE CERVIX CARCINOMA;

EID: 62849114529     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2009.01.003     Document Type: Review

References (127)

1. Vanhaesebroeck B., et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70 (2001) 535-602
2. Stephens L.R., et al. The Gβγ sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 89 (1997) 105-114
3. Suire S., et al. p84, a new Gβγ-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110. Curr. Biol. 15 (2005) 566-570
4. Voigt P., et al. Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase γ that is highly expressed in heart and interacts with PDE3B. J. Biol. Chem. 281 (2006) 9977-9986
5. Guillermet-Guibert J., et al. The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 8292-8297
6. Barbier M., et al. Tumour biology. Weakening link to colorectal cancer?. Nature 413 (2001) 796
7. Li Z., et al. Roles of PLC-2 and -3 and PI3K in chemoattractant-mediated signal transduction. Science 287 (2000) 1046-1049
8. Vanhaesebroeck B., et al. p110δ, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4330-4335
9. Chantry D., et al. p110δ, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J. Biol. Chem. 272 (1997) 19236-19241
10. Yang N., et al. Transcriptional regulation of PIK3CA oncogene by NF-κB in ovarian cancer microenvironment. PLoS ONE 3 (2008) e1758
11. El Sheikh S.S., et al. Topographical expression of class IA and class II phosphoinositide 3-kinase enzymes in normal human tissues is consistent with a role in differentiation. BMC Clin. Pathol. 3 (2003) 4
12. Foukas L.C., et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441 (2006) 366-370
13. Okkenhaug K., et al. Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 297 (2002) 1031-1034
14. Eickholt B.J., et al. Control of axonal growth and regeneration of sensory neurons by the p110δ PI 3-Kinase. PLoS One 2 (2007) e869
15. Fry M.J., et al. Purification and characterization of a phosphatidylinositol 3-kinase complex from bovine brain by using phosphopeptide affinity columns. Biochem. J. 288 (1992) 383-393
16. Kazlauskas A., and Cooper J.A. Phosphorylation of the PDGF receptor β subunit creates a tight binding site for phosphatidylinositol 3 kinase. EMBO J. 9 (1990) 3279-3286
17. Yu J., et al. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110α catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 18 (1998) 1379-1387
18. Brachmann S.M., et al. Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol. Cell. Biol. 25 (2005) 2593-2606
19. Zhao J.J., et al. The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 16296-16300
20. Geering B., et al. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 7809-7814
21. Luo J., and Cantley L.C. The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer. Cell Cycle 4 (2005) 1309-1312
22. Chen D., et al. p50α/p55α phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. Mol. Cell. Biol. 24 (2004) 320-329
23. Fruman D.A., et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 α. Nat. Genet. 26 (2000) 379-382
24. Terauchi Y., et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 α subunit of phosphoinositide 3-kinase. Nat. Genet. 21 (1999) 230-235
25. Ueki K., et al. Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 419-424
26. Geering B., et al. Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits? Biochem. Soc. Trans. 35 (2007) 199-203
27. del Rincon J.P., et al. Growth hormone regulation of p85α expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 56 (2007) 1638-1646
28. Rieusset J., et al. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor γ with Rosiglitazone (BRL 49653) in human adipocytes. Biochem. Biophys. Res. Commun. 265 (1999) 265-271
29. Rieusset J., et al. The expression of the p85α subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor γ in human adipocytes. Diabetologia 44 (2001) 544-554
30. Rieusset J., et al. Regulation of p85α phosphatidylinositol-3-kinase expression by peroxisome proliferator-activated receptors (PPARs) in human muscle cells. FEBS Lett. 502 (2001) 98-102
31. Andreelli F., et al. Defective regulation of phosphatidylinositol-3-kinase gene expression in skeletal muscle and adipose tissue of non-insulin-dependent diabetes mellitus patients. Diabetologia 42 (1999) 358-364
32. Andreelli F., et al. Regulation of gene expression during severe caloric restriction: lack of induction of p85 α phosphatidylinositol 3-kinase mRNA in skeletal muscle of patients with type II (non-insulin-dependent) diabetes mellitus. Diabetologia 43 (2000) 356-363
33. Barbour L.A., et al. Increased P85α is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J. Biol. Chem. 280 (2005) 37489-37494
34. Ducluzeau P.H., et al. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes 50 (2001) 1134-1142
35. Bastien J., et al. The phosphoinositide 3-kinase/Akt pathway is essential for the retinoic acid-induced differentiation of F9 cells. Oncogene 25 (2006) 2040-2047
36. Esposito I., et al. The cannabinoid CB1 receptor antagonist Rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating phosphatidylinositol-3-kinase activity. Mol. Pharmacol. 74 (2008) 1678-1686
37. Laville M., et al. Acute regulation by insulin of phosphatidylinositol-3-kinase, Rad, Glut 4, and lipoprotein lipase mRNA levels in human muscle. J. Clin. Invest. 98 (1996) 43-49
38. Lefai E., et al. Expression of the splice variants of the p85α regulatory subunit of phosphoinositide 3-kinase in muscle and adipose tissue of healthy subjects and type 2 diabetic patients. Biochem. J. 360 (2001) 117-126
39. Lee Y.R., et al. Up-regulation of PI3K/Akt signaling by 17β-estradiol through activation of estrogen receptor-α, but not estrogen receptor-β, and stimulates cell growth in breast cancer cells. Biochem. Biophys. Res. Commun. 336 (2005) 1221-1226
40. Pankow S., et al. Regulation of epidermal homeostasis and repair by phosphoinositide 3-kinase. J. Cell Sci. 119 (2006) 4033-4046
41. Asano T., et al. p110β Is Up-regulated during differentiation of 3T3-L1 cells and contributes to the highly insulin-responsive glucose transport activity. J. Biol. Chem. 275 (2000) 17671-17676
42. Astanehe A., et al. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J. Cell Sci. 121 (2008) 664-674
43. Hui R.C., et al. The forkhead transcription factor FOXO3a increases PI3K/Akt activity in drug-resistant leukaemic cells through induction of PIK3CA expression. Mol. Cell. Biol. 28 (2008) 5886-5898
44. Hirsch E., et al. Analysis of the murine phosphoinositide 3-kinase γ gene. Gene 256 (2000) 69-81
45. Abell K., et al. Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat. Cell Biol. 7 (2005) 392-398
46. Spender L.C., et al. Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55α regulatory subunit of PI3-kinase and its role in survival of EREB2. 5 cells. J. Gen. Virol. 87 (2006) 2859-2867
47. Kallin A., et al. SREBP1 regulates the expression of heme oxygenase 1 and the phosphatidylinositol-3 kinase regulatory subunit p55γ. J. Lipid Res. 48 (2007) 1628-1636
48. Park S.Y., et al. miR-29 miRNAs activate p53 by targeting p85α and CDC42. Nat. Struct. Mol. Biol. 16 (2009) 23-29
49. Guo C., et al. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 47 (2008) 939-946
50. Ito Y., et al. Enhanced gene expression for phosphatidylinositol 3-kinase in the hypoglossal motoneurons following axonal crush. Brain Res. Mol. Brain Res. 37 (1996) 329-332
51. Okamoto T., et al. Differential regulation of the regulatory subunits for phosphatidylinositol 3-kinase in response to motor nerve injury. Brain Res. Mol. Brain Res. 131 (2004) 119-125
52. Northcott C.A., et al. Upregulated function of phosphatidylinositol-3-kinase in genetically hypertensive rats: a moderator of arterial hypercontractility. Clin. Exp. Pharmacol. Physiol. 32 (2005) 851-858
53. Northcott C.A., et al. PI3-Kinase upregulation and involvement in spontaneous tone in arteries from DOCA-salt rats: is p110δ the culprit?. Hypertension 43 (2004) 885-890
54. Northcott C.A., et al. Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats. Circ. Res. 91 (2002) 360-369
55. Baier R., et al. Retinoic acid induces selective expression of phosphoinositide 3-kinase γ in myelomonocytic U937 cells. Cell Growth Differ. 10 (1999) 447-456
56. Barbour L.A., et al. Human placental growth hormone increases expression of the p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. Endocrinology 145 (2004) 1144-1150
57. Dominici F.P., et al. Alterations in the early steps of the insulin-signaling system in skeletal muscle of GH-transgenic mice. Am. J. Physiol. 277 (1999) E447-E454
58. Bi L., et al. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274 (1999) 10963-10968
59. Singh B., et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev. 16 (2002) 984-993
60. Rohrbach A., et al. Selective downregulation of phosphoinositide 3-kinase α in leukocytes during pregnancy. Am. J. Reprod. Immunol. 61 (2009) 130-135
61. Samuels Y., and Ericson K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18 (2006) 77-82
62. Samuels Y., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
63. Ma Y.Y., et al. PIK3CA as an oncogene in cervical cancer. Oncogene 19 (2000) 2739-2744
64. Shayesteh L., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21 (1999) 99-102
65. Byun D.S., et al. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int. J. Cancer 104 (2003) 318-327
66. Hu P., et al. Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol. Cell. Biol. 13 (1993) 7677-7688
67. Bi L., et al. Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase. Mamm. Genome 13 (2002) 169-172
68. Le Stunff C., et al. Association analysis indicates that a variant GATA-binding site in the PIK3CB promoter is a Cis-acting expression quantitative trait locus for this gene and attenuates insulin resistance in obese children. Diabetes 57 (2008) 494-502
69. Zhang L., et al. Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin. Cancer Res. 13 (2007) 5314-5321
70. Liu Z., et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab. 93 (2008) 3106-3116
71. Zhu Q., et al. Phosphoinositide 3-OH kinase p85α and p110β are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 27 (2008) 4569-4579
72. Boller D., et al. Targeting the phosphoinositide 3-kinase isoform p110δ impairs growth and survival in neuroblastoma cells. Clin. Cancer Res. 14 (2008) 1172-1181
73. Sawyer C., et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110δ. Cancer Res. 63 (2003) 1667-1675
74. Geng L., et al. A specific antagonist of the p110δ catalytic component of phosphatidylinositol 3′-kinase, IC486068, enhances radiation-induced tumor vascular destruction. Cancer Res. 64 (2004) 4893-4899
75. Puri K.D., et al. The role of endothelial PI3Kγ activity in neutrophil trafficking. Blood 106 (2005) 150-157
76. Billottet C., et al. A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25 (2006) 6648-6659
77. Sujobert P., et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106 (2005) 1063-1066
78. Knobbe C.B., and Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 13 (2003) 507-518
79. Alloatti G., et al. Phosphoinositide 3-kinase γ controls autonomic regulation of the mouse heart through Gi-independent downregulation of cAMP level. FEBS Lett. 579 (2005) 133-140
80. Patrucco E., et al. PI3Kγ modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118 (2004) 375-387
81. Stoyanov B., et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 269 (1995) 690-693
82. Li L.X., et al. Role of phosphatidylinositol 3-kinaseγ in the β-cell: interactions with glucagon-like peptide-1. Endocrinology 147 (2006) 3318-3325
83. MacDonald P.E., et al. Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased β-cell mass in mice lacking the p110γ isoform of phosphoinositide 3-kinase. Endocrinology 145 (2004) 4078-4083
84. Vecchione C., et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kγ. J. Exp. Med. 201 (2005) 1217-1228
85. Zhao M., et al. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-γ and PTEN. Nature 442 (2006) 457-460
86. Hickey F.B., and Cotter T.G. BCR-ABL regulates phosphatidylinositol 3-Kinase-p110γ transcription and activation and is required for proliferation and drug resistance. J. Biol. Chem. 281 (2006) 2441-2450
87. Inukai K., et al. A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK Is generated by alternative splicing of the p85α gene. J. Biol. Chem. 271 (1996) 5317-5320
88. Inukai K., et al. p85α gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-Kinase), p50α, p55α, and p85α, with different PI 3-kinase activity elevating responses to insulin. J. Biol. Chem. 272 (1997) 7873-7882
89. Bandyopadhyay G.K., et al. Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54 (2005) 2351-2359
90. Catalano P.M., et al. Downregulated IRS-1 and PPARγ in obese women with gestational diabetes: relationship to FFA during pregnancy. Am. J. Physiol. Endocrinol. Metab. 282 (2002) E522-E533
91. Friedman J.E., et al. Impaired glucose transport and insulin receptor tyrosine phosphorylation in skeletal muscle from obese women with gestational diabetes. Diabetes 48 (1999) 1807-1814
92. Tsuchida H., et al. Gene expression of the p85α regulatory subunit of phosphatidylinositol 3-kinase in skeletal muscle from type 2 diabetic subjects. Pflugers Arch. 445 (2002) 25-31
93. Shepherd P.R., et al. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem. J. 333 (1998) 471-490
94. Kerouz N.J., et al. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J. Clin. Invest. 100 (1997) 3164-3172
95. Rieusset J., et al. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-γ in human adipocytes. Diabetes 48 (1999) 699-705
96. Castoria G., et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 20 (2001) 6050-6059
97. Simoncini T., et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000) 538-541
98. Banerjee S., et al. 17α-estradiol-induced VEGF-A expression in rat pituitary tumor cells is mediated through ER independent but PI3K-Akt dependent signaling pathway. Biochem. Biophys. Res. Commun. 300 (2003) 209-215
99. Fruman D.A., et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85α. Science 283 (1999) 393-397
100. Ueki K., et al. Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85α regulatory subunit. Mol. Cell. Biol. 20 (2000) 8035-8046
101. Ueki K., et al. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol. Cell. Biol. 22 (2002) 965-977
102. Fish J.E., et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 15 (2008) 272-284
103. Abell K., and Watson C.J. The Jak/Stat pathway: a novel way to regulate PI3K activity. Cell Cycle 4 (2005) 897-900
104. Fruman D.A., et al. Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 α gene. Genomics 37 (1996) 113-121
105. Antonetti D.A., et al. Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain. Mol. Cell. Biol. 16 (1996) 2195-2203
106. Pons S., et al. The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. Mol. Cell. Biol. 15 (1995) 4453-4465
107. Demoulin J.B., et al. Platelet-derived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory element-binding proteins. J. Biol. Chem. 279 (2004) 35392-35402
108. Hawkins P.T., et al. Signalling through Class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34 (2006) 647-662
109. Rusten T.E., and Stenmark H. Analyzing phosphoinositides and their interacting proteins. Nat. Methods 3 (2006) 251-258
110. Pettitt T.R., et al. Analysis of intact phosphoinositides in biological samples. J. Lipid Res. 47 (2006) 1588-1596
111. Bernstein H.G., et al. Tissue distribution and subcellular localization of a G-protein activated phosphoinositide 3-kinase. An immunohistochemical study. Cell Mol. Biol. (Noisy-le-grand) 44 (1998) 973-983
112. Hirsch E., et al. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science 287 (2000) 1049-1053
113. Domin J., et al. Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem. J. 326 (1997) 139-147
114. Brown R.A., et al. Identification and cDNA cloning of a novel mammalian C2 domain-containing phosphoinositide 3-kinase, HsC2-PI3K. Biochem. Biophys. Res. Commun. 233 (1997) 537-544
115. Misawa H., et al. Cloning and characterization of a novel class II phosphoinositide 3-kinase containing C2 domain. Biochem. Biophys. Res. Commun. 244 (1998) 531-539
116. Ono F., et al. A novel class II phosphoinositide 3-kinase predominantly expressed in the liver and its enhanced expression during liver regeneration. J. Biol. Chem. 273 (1998) 7731-7736
117. Rozycka M., et al. cDNA cloning of a third human C2-domain-containing class II phosphoinositide 3-kinase, PI3K-C2γ, and chromosomal assignment of this gene (PIK3C2G) to 12p12. Genomics 54 (1998) 569-574
118. Panaretou C., et al. Characterization of p150, an adaptor protein for the human phosphatidylinositol (PtdIns) 3-kinase. Substrate presentation by phosphatidylinositol transfer protein to the p150. Ptdins 3-kinase complex. J. Biol. Chem. 272 (1997) 2477-2485
119. Volinia S., et al. A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system. EMBO J. 14 (1995) 3339-3348
120. Fenic I., et al. Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol. Rep. 18 (2007) 253-259
121. Sticht C., et al. Amplification of Cyclin L1 is associated with lymph node metastases in head and neck squamous cell carcinoma (HNSCC). Br. J. Cancer 92 (2005) 770-774
122. Massion P.P., et al. early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am. J. Respir. Crit. Care Med. 170 (2004) 1088-1094
123. Falasca M., and Maffucci T. Role of class II phosphoinositide 3-kinase in cell signalling. Biochem. Soc. Trans. 35 (2007) 211-214
124. Traer C.J., et al. Are class II phosphoinositide 3-kinases potential targets for anticancer therapies? Bull. Cancer 93 (2006) E53-E58
125. Ho L.K., et al. Identification of four novel human phosphoinositide 3-kinases defines a multi-isoform subfamily. Biochem. Biophys. Res. Commun. 235 (1997) 130-137
126. Arcaro A., et al. Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J. 21 (2002) 5097-5108
127. Backer J.M. The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem. J. 410 (2008) 1-17